Leyden Labs: $70 Million Secured For Advancing Intranasal Antibody Programs
By Amit Chowdhry ● Jan 12, 2025
Leyden Laboratories announced it has raised $70 million in funding to advance its Mucosal Protection Platform. This funding round was supported by co-leads ClavystBio and Polaris Partners, with participation by Qiming Venture Partners and existing investors. And the company’s syndicate of VC investors now includes GV (formerly Google Ventures), Casdin Capital, F-Prime Capital, ClavystBio, Polaris Partners, Qiming Venture Partners, Invus, Byers Capital / Brook Byers, Bluebird Ventures, and Softbank Vision Fund 2.